How Ph.D. was paid
$5.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Bassil I. Dahiyat, Ph.D.President, Chief Executive Officer and Director | $742,800 | $1,552,892 | $2,727,018 | $490,248 | $8,247 | $5,521,205 |
| Bart Jan CornelissenChief Financial Officer | $491,600 | $310,578 | $515,712 | $243,342 | $81,164 | $1,642,396 |
| John R. Desjarlais, Ph.D.Chief Scientific Officer | $547,900 | $422,392 | $701,368 | $301,345 | $9,247 | $1,982,252 |
| Celia E. EckertGeneral Counsel | $491,600 | $310,578 | $515,712 | $243,342 | $9,247 | $1,570,479 |
| Nancy K. Valente, M.D.Former Chief Development Officer | $249,421 | — | — | — | $181,345 | $430,766 |
What changed and why
- 90%90% of the CEO's target total compensation was variable and at risk.
- 110%The HCMCC approved a corporate goal achievement level of 110% based on 2025 performance.
- $6.8MCEO total compensation decreased from $6,811,829 in 2024 to $5,521,205 in 2025.
- 97.9%At the 2025 annual meeting, approximately 97.9% of votes cast approved the advisory say-on-pay vote.
- $610.8MThe company ended 2025 with $610.8 million in cash, cash equivalents, and marketable debt securities.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.